<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03192150</url>
  </required_header>
  <id_info>
    <org_study_id>C-16-305-003</org_study_id>
    <nct_id>NCT03192150</nct_id>
  </id_info>
  <brief_title>Independent Comparative Study to Evaluate ISV-305 Compared to Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery</brief_title>
  <acronym>ISV-305</acronym>
  <official_title>A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite® 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>InSite Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>InSite Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the ocular safety, tolerability, and efficacy of
      ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of inflammation
      and pain associated with cataract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 3, 2018</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anterior Chamber Cell Grade 0</measure>
    <time_frame>Day 15</time_frame>
    <description>Primary efficacy endpoint for the comparison of ISV-305 and Vehicle</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Inflammation and Pain Associated With Cataract Surgery</condition>
  <arm_group>
    <arm_group_label>ISV-305</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1% dexamethasone in DuraSite® 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>DuraSite® 2 vehicle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISV-305</intervention_name>
    <description>Dexamethasone in DuraSite® 2 twice daily for 16 days</description>
    <arm_group_label>ISV-305</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle twice daily for 16 days</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are at least 17 years of age

          -  Are scheduled for uncomplicated unilateral cataract surgery

          -  Signature of the subject or parent(s) or legally authorized representative on the
             Informed Consent Form, and when appropriate the minor's assent in accordance with
             local regulations

          -  Are willing and able to follow all instructions and attend all study visits

          -  Are willing to avoid disallowed medication for the duration of the study

          -  If female is of childbearing potential, agree to and submit a urine sample for
             pregnancy testing (prior to enrollment and at the end of the study) and use effective
             contraception for the duration of the study

          -  Male subjects whose female partners are not post-menopausal must agree to one of the
             following: 1) completely abstain from sexual intercourse, 2) use a barrier method
             (condoms) with spermicide during sexual intercourse for the duration of the study, 3)
             provide documentation for having had a vasectomy (with documented infertility)

          -  Additional inclusion criteria also apply

        Exclusion Criteria:

          -  Have known sensitivity or poor tolerance to any component of the study drugs

          -  Have any sign of iritis or scleritis in the study eye

          -  Have an acute ocular infection (bacterial, viral or fungal) or active ocular
             inflammation in the study eye

          -  Have any active or chronic/recurrent ocular or systemic disease that is uncontrolled
             and likely to affect wound healing (e.g., diabetes mellitus, systemic connective
             tissue disease, severe atopic disease)

          -  Have known blood dyscrasia or bone marrow suppression

          -  Have any active corneal pathology in the study eye

          -  Have had radial keratotomy, corneal transplant, or LASIK in the study eye within the
             last 2 years

          -  Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine
             pregnancy test

          -  Have prior (within 30 days of beginning study treatment) or anticipated concurrent use
             of an investigational drug or device

          -  Have a condition or a situation which, in the investigator's opinion, may put the
             subject at increased risk, confound study data, or interfere significantly with the
             subject's study participation

          -  Use of any medication the investigator feels may interfere with the study parameters

          -  Additional exclusion criteria also apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 15, 2017</study_first_submitted>
  <study_first_submitted_qc>June 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

